The WHO has set out a new blueprint for dementia research: outlining the potential of precision medicine, repurposed drugs and revamped clinical trials. “Addressing dementia is one of the greatest health challenges of our generation,” says the organization.
Cardiff-based CatSci is investing in its oligonucleotides capability that will enable the company to make oligos from nanomole quantities up to 30 grams using solid phase synthesis.
Eli Lilly and Company will acquire Akouos, a precision genetic medicine company developing a portfolio of adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss.
GSK’s respiratory syncytial virus (RSV) vaccine for adults aged 60+ has demonstrated overall vaccine efficacy of 82.6% against RSV lower respiratory tract disease (RSV-LRTD) - and a 94.1% reduction in severe RSV - in Phase 3 trials.
Merck has exercised its option to jointly develop and commercialize a personalized cancer vaccine (PVC) with Moderna following 'significant progress' made by the two companies in the field to date.
Intranasal delivery of ChAdOx1 nCoV-19 failed to induce either a consistent mucosal antibody response or a strong systemic immune response, according to results from a Phase 1 clinical trial released today. However, researchers say delivery of vaccines...
BioNTech will establish an mRNA research and innovation center in Victoria, alongside clinical scale manufacturing capabilities. Meanwhile, it has also pledged to step up clinical development of oncology therapies in the country.
Lumen Bioscience says new data has been released demonstrating that its needle-free, spirulina-produced recombinant vaccinate protects against malaria.
Biogen has started a global Phase 2/3 study for litifilimab, a humanized IgG1 monoclonal antibody (mAb), in participants with cutaneous lupus erythematosus (CLE).
Kibow Biotech is celebrating its 25th anniversary as the company pivots toward developing a drug based on its proprietary probiotic strains that benefit kidney disease suffers.
Samsung Biologics has introduced two new platforms focused on optimized antibody production and systematic screening of molecules at an early development stage.
Vitamin D supplementation does not influence the efficacy or immunogenicity of SARS-CoV-2 vaccinations in patients with sub-optimal levels prior to vitamin treatment, according to a new study.
VBI Vaccines has started enrollment in a Phase 1 clinical study of VBI-2901, a multivalent enveloped virus-like particle (eVLP) coronavirus vaccine candidate targeting SARS, COVID-19 and MERS.
An investigational Alzheimer's drug made by Eisai Co Ltd and Biogen slowed cognitive and functional decline in a trial involving a large group of patients in the early stages of the disease.
The US National Institutes of Health plans to invest $130m in accelerating the widespread use of artificial intelligence (AI) by the biomedical and behavioral research communities through its Bridge2AI program.
San Francisco based Cellares is partnering with Lexington, Massachusetts headquartered iVexSol to accelerate and improve the quality of viral vector manufacturing and transduction.
An extension of a Phase 3 trial for Biogen’s tofersen shows benefits in a form of motor neuron disease, according to a study published in the New England Journal of Medicine (NEJM) this week.
Vaxxas will receive an AU$8.2m second round grant to support the manufacturing scale-up of its technology that enables vaccines to be applied to the skin using a small patch.
Rocket Pharmaceuticals, a late-stage, clinical biotech advancing a pipeline of genetic therapies for rare childhood disorders, will acquire Renovacor: helping it strengthen its position in AAV-based cardiac gene therapy.
Pfizer will submit a Biologics License Application (BLA) for its investigational pentavalent meningococcal vaccine (MenABCWY) to the US Food and Drug Administration (FDA) later this year, following positive top-line results from a Phase 3 trial.
Novo Nordisk and Microsoft have entered a new strategic collaboration to combine Microsoft’s computational services, cloud, and artificial intelligence (AI) with Novo Nordisk’s drug discovery, development, and data science capabilities.
UK-based biopharmaceutical company, PhoreMost, is to deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER, toward disease-relevant pathways nominated by Roche.
What role does Bioprocessing 4.0 have to play in the ongoing energy crisis? How can we train and develop the right skills for the industry? These are just some of the questions we’ll ask in our free-to-attend webinar tomorrow!
Experts from the health information specialist explain how the use of RWD and RWE has helped speed up and improve the development of therapies and vaccines.
Technology firm, Benchling, has developed what it calls the biopharma industry’s first set of full capabilities for designing, modelling, and studying both natural and chemically modified RNA in a single platform.
Bioprocessing 4.0 and digitalization is all about embracing new technologies to enable faster, smoother and more efficient biomanufacturing. And that also requires embracing a new mindset.
Ori Biotech, a company aiming to bring automated manufacturing to the CGT industry, has been executing its strategic plan following the US$100m it raised in its Series B funding round earlier this year.
Arcturus Therapeutics has obtained an award for up to $63.2m from the Biomedical Advanced Research and Development Authority (BARDA): allowing the company to expand its current influenza vaccine program to include development of a pandemic influenza vaccine...
As environmental considerations move up the agenda for biopharmaceutical manufacturers, process intensification can offer a win-win situation for those looking to lower costs and improve sustainability.
Process intensification is the natural next step for the biopharma industry as it transitions from a focus on global blockbuster drugs to a diversified portfolio of specialized biopharmaceuticals, finds a study.
The compelling benefits of single-use technologies (SUT) have been demonstrated in bioprocessing for many years. They are deemed to have a role to play in facilitating process intensification through enabling low capital costs and fast change-over time...
BrainVectis, a subsidiary of AskBio, has received clearance from the French authorities to start a Phase 1-2 clinical trial for its novel Huntington’s Disease gene therapy, BV-101.
The WHO has updated its advice on COVID-19 booster doses: including recommendations on which groups should receive a second booster shot and how countries should plan around the upcoming availability of variant-specific vaccines.
West Pharmaceutical Services has made an investment in Latch Medical, a Dublin-based company working on next-generation vaccine and biologics delivery technology.
The AI and QC specialists have joined to use AI and QC in order to discover biological pathways relevant to the treatment of triple-negative breast cancer.
Merck and Orna Therapeutics have announced a collaboration agreement to discover, develop and commercialize Orna’s next generation oRNA technology across multiple programs, including vaccines and therapeutics in infectious disease and oncology.
The pharmaceutical company has inked a strategic collaboration with the drug discovery firm, centering on uncovering novel targets in Alzheimer’s disease.
Biopharmaceutical company Global Blood Therapeutics specializes in conditions that often disproportionately impact underrepresented communities, such as SCD.
BioNTech and Genmab are expanding a global collaboration to develop and commercialize novel immunotherapies for the treatment of cancer patients: with the first monospecific antibody candidate expected to enter clinical trials by the end of the year.
Vaxess Technologies has launched a phase 1 trial for its H1 influenza vaccine patch: outlining its mission to increase access to vaccines via the shelf-stable, sustained-release patch.
With speculation that Merck is lining up a multi-billion dollar acquisition in the ADC space, the company has agreed a second collaboration deal with Sichuan Kelun Pharmaceutical.
